No Data
No Data
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock (NASDAQ:SRRK, the "Company")), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where
Scholar Rock Holding Is Maintained at Outperform by BMO Capital
Scholar Rock Holding Is Maintained at Outperform by BMO Capital
BMO Capital Maintains Scholar Rock(SRRK.US) With Buy Rating, Raises Target Price to $31
BMO Capital analyst Etzer Darout maintains $Scholar Rock(SRRK.US)$ with a buy rating, and adjusts the target price from $29 to $31.According to TipRanks data, the analyst has a success rate of 58.7% a
Express News | Scholar Rock Holding Corp : BMO Raises Target Price to $31 From $29
BMO Capital Maintains Scholar Rock(SRRK.US) With Buy Rating, Maintains Target Price $29
BMO Capital analyst Etzer Darout maintains $Scholar Rock(SRRK.US)$ with a buy rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of 58.7% and a to
Truist Financial Maintains Scholar Rock(SRRK.US) With Buy Rating
Truist Financial analyst Srikripa Devarakonda maintains $Scholar Rock(SRRK.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 48.9% and a total average return of 5.5%
No Data